|Allon Announces New Findings Of Davunetide. Luminex Receives FDA Clearance for Respiratory Viral Panel Test.|
|By Staff and Wire Reports|
|Tuesday, 19 July 2011 19:16|
Allon Therapeutics Inc. (Public, TSE:NPC) announced new findings that 12 weeks of treatment with the Company's lead product davunetide appears to prevent cortical thinning of important parts of the brains of schizophrenia patients.
The analyses showed that the greatest treatment effect was seen in the dorsolateral prefrontal and temporal cortical regions of the brain. These areas are known to be impacted in cognitive-impairment associated with schizophrenia (CIAS).
The ongoing imaging analysis is part of the study data collected as part of a larger Phase 2a clinical trial, which showed a statistically significant (p=0.015) effect on the functional outcome measure, the UCSD (University of California at San Diego) Performance-based Skills Assessment (UPSA).
The UPSA test assesses the functional capacity of skills for daily living and has been recognized by drug regulators as an appropriate co-primary endpoint in patients suffering from CIAS.
Luminex Corporation (Public, NASDAQ:LMNX) announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its xTAG Respiratory Viral Panel FAST (RVP FAST).
This front line test has the potential to significantly change the way respiratory viral testing is performed and complements the company's existing respiratory portfolio.
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, is being covered by TRICARE, the U.S. military health plan for active duty service members and retirees of the seven uniformed services, their family members, survivors and others who are registered in the Defense Enrollment Eligibility Reporting System (DEERS).
Adia Nutrition, a division of 3Me, Inc. (PINKSHEETS: PIVX), is proud to announce the following four marketing initiatives: Adia Nutrition probiotic powder is now available in over 30 retail locations in Orange County, California and Boston, Massachusetts.
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has formed an alliance with Bio-Stasis International, Inc., a dietary supplement internet marketer, to launch Bio-Stasis International's Virapress. Bio-Stasis plans to embark on an extensive internet marketing program for Virapress on August 1, 2011, targeting alternative and complimentary medical practitioners.
AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging in vitro diagnostic company, reported substantial progress in the development of AppyScore™, the first blood-based testing system designed to help physicians manage the millions of patients who enter emergency rooms every year complaining of abdominal pain and suspected of having acute appendicitis but at low risk for the disease.
BioMed Realty Trust, Inc. (NYSE:BMR) announced today that the company has entered into a new $750 million unsecured revolving credit facility, replacing the previous unsecured revolving credit facility which had a maturity date of August 1, 2011.
Luminex Corporation (Nasdaq:LMNX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its xTAG Respiratory Viral Panel FAST (RVP FAST).
Medco Health Solutions, Inc. (NYSE:MHS) today announced new offerings within its Advanced Oncology Solutions™, that include treatment pathways decision support with embedded pharmacogenomic testing and nutrition recommendations for cancer patients.
NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company, announced today the pricing of an underwritten public offering of 13,750,000 units at $1.20 per unit.
The following is my Play-by-Play recap of a recent City Council Meeting in which Positron Corporation (OTCBB:POSC) had big stakes.
Radient Pharmaceuticals Corporation (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced the company will hold its annual shareholder meeting at its corporate headquarters located at 2492 Walnut Avenue, Suite 100, Tustin, California, 92780, on Friday, August 19, 2011 at 11:00 a.m. (PDT).
Southern Home Medical Equipment, Inc. (PINKSHEETS: SHOM), a holding company providing healthcare services, staffing and durable medical equipment to medical institutions, announced today its record financial results for the three months ended June 30, 2011.
Sun Healthcare Group, Inc. (NASDAQ: SUNH) invites investors to listen to a conference call with Sun's senior management on Tuesday, Aug. 2, 2011, at 10 a.m. Pacific / 1 p.m. Eastern to discuss the Company's second-quarter results for 2011.
Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, today announced that it will release second quarter 2011 financial results before the market opens on Thursday, August 11, 2011.
A dispatch trade report about TapImmune (OTCBB: TPIV) informs readers at BioMedReports that biotech analysts are anticipating good news on several fronts for the company's ongoing collaborative research programs.
WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2011 after the New York Stock Exchange closes on Wednesday, August 10, 2011 (which will be Thursday morning, August 11, 2011 Shanghai time).